Carlsmed (CARL) Cash & Equivalents (2024 - 2026)

Carlsmed (CARL) has reported Cash & Equivalents for 3 consecutive years, with $89.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 166.79% year-over-year to $89.3 million; the trailing twelve-month figure through Jun 2026 stood at $89.3 million (up 166.79% YoY), and the FY2025 full-year result was $85.8 million, up 113.81% from the prior year.
• Cash & Equivalents slipped to $89.3 million in Q2 2026 per CARL's latest filing, from $97.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $115.4 million in Q3 2025 and bottomed at $33.5 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $65.2 million across 3 years, with a median of $44.4 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents fell 12.26% in 2025, then jumped 166.79% in 2026.
• Over 3 years, Cash & Equivalents stood at $40.1 million in 2024, then soared by 113.81% to $85.8 million in 2025, then advanced by 4.09% to $89.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $89.3 million, $97.1 million, and $85.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.